<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1526</journal-id><journal-id journal-id-type="pmc-domain">frontmicrobio</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4916179</article-id><article-id pub-id-type="pmcid-ver">PMC4916179.1</article-id><article-id pub-id-type="pmcaid">4916179</article-id><article-id pub-id-type="pmcaiid">4916179</article-id><article-id pub-id-type="pmid">27446011</article-id><article-id pub-id-type="doi">10.3389/fmicb.2016.00970</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Opioids and Viral Infections: A Double-Edged Sword</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tahamtan</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/343119/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tavakoli-Yaraki</surname><given-names initials="M">Masoumeh</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/263866/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mokhtari-Azad</surname><given-names initials="T">Talat</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teymoori-Rad</surname><given-names initials="M">Majid</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bont</surname><given-names initials="L">Louis</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shokri</surname><given-names initials="F">Fazel</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salimi</surname><given-names initials="V">Vahid</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/342869/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Virology, School of Public Health, Tehran University of Medical Sciences</institution><country>Tehran, Iran</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biochemistry, School of Medicine, Iran University of Medical Sciences</institution><country>Tehran, Iran</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht</institution><country>Utrecht, Netherlands</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Immunology, School of Public Health, Tehran University of Medical Sciences</institution><country>Tehran, Iran</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Slobodan Paessler, University of Texas Medical Branch, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Venkata Subba Rao Atluri, Florida International University, USA; Kelly Dineley, The University of Texas Medical Branch at Galveston, USA</p></fn><corresp id="fn001">*Correspondence: Vahid Salimi<email>vsalimi@tums.ac.ir</email>; <email>vahidsalimii@gmail.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><issue-id pub-id-type="pmc-issue-id">263737</issue-id><elocation-id>970</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>6</month><year>2016</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>06</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>21</day><month>07</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-15 13:25:32.263"><day>15</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2016 Tahamtan, Tavakoli-Yaraki, Mokhtari-Azad, Teymoori-Rad, Bont, Shokri and Salimi.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Tahamtan, Tavakoli-Yaraki, Mokhtari-Azad, Teymoori-Rad, Bont, Shokri and Salimi</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmicb-07-00970.pdf"/><abstract><p>Opioids and their receptors have received remarkable attention because they have the ability to alter immune function, which affects disease progression. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> findings as well as observations in humans indicate that opioids and their receptors positively or negatively affect viral replication and virus-mediated pathology. The present study reviews recent insights in the role of opioids and their receptors in viral infections and discusses possible therapeutic opportunities. This review supports the emerging concept that opioids and their receptors have both favorable and unfavorable effects on viral disease, depending on the type of virus. Targeting of the opioid system is a potential option for developing effective therapies; however caution is required in relation to the beneficial functions of opioid systems.</p></abstract><kwd-group><kwd>opioids</kwd><kwd>opioid receptors</kwd><kwd>immunomodulation</kwd><kwd>viral infections</kwd><kwd>therapies</kwd><kwd>immune responses</kwd><kwd>opioid signaling</kwd><kwd>anti-inflammation</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Tehran University of Medical Sciences and Health Services<named-content content-type="fundref-id">10.13039/501100004484</named-content></funding-source><award-id rid="cn001">28054</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="0"/><ref-count count="129"/><page-count count="14"/><word-count count="10168"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Opioids and their receptors</title><p>Opioids are a group of endogenous and exogenous/synthetic compounds that function through activation of opioid receptors (McNally and Akil, <xref rid="B58" ref-type="bibr">2002</xref>). Opioid receptors have been isolated, cloned, and classified as &#956;-opioid receptors (MORs), &#948;-opioid receptors (DORs), &#954;-opioid receptors (KORs), and opioid-like receptors (ORL), and are encoded by OPRM1, OPRD1, OPRK1, and OLR genes, respectively (Stevens, <xref rid="B102" ref-type="bibr">2009</xref>). The MOR (&#956;1, &#956;2, &#956;3), DOR (&#948;1, &#948;2), and KOR (&#954;1, &#954;2, &#954;3) opioid receptor genes have been cloned (Herz, <xref rid="B34" ref-type="bibr">1998</xref>). Opioid receptors are mainly distributed in the central and peripheral nervous system, as well as in non-neuronal cells in the lung, spleen, liver, intestine, adenoid, and kidney (Wittert et al., <xref rid="B124" ref-type="bibr">1996</xref>).</p><p>The receptors are transmembrane G protein-coupled receptors (GPCRs) with an affinity for endogenous opioid peptides and include &#946;-endorphin, encephalin, met-enkephalin, nociceptin, and exogenous natural and synthetic opioid agents (e.g., morphine, heroin; Stein, <xref rid="B101" ref-type="bibr">2016</xref>). A high degree of structural similarity (50&#8211;70%) has been observed in the transmembrane domains 2, 3, and 7 and the first and second intracellular loops. The extracellular domain diverges, which explains differences in ligand selectivity between opioid receptors (McNally and Akil, <xref rid="B58" ref-type="bibr">2002</xref>). Following activation of the opioid receptors, adenylyl cyclase is inhibited, which activates K<sup>+</sup> channels and diminishes the conductance of voltage-sensitive Ca<sup>2+</sup> channels (Stein, <xref rid="B101" ref-type="bibr">2016</xref>). Opioid receptors also activate mitogen-activated protein kinases (MAPK) and phospholipase C-mediated signaling, leading to the formation of IP3 and diacyl glycerol (Childers, <xref rid="B14" ref-type="bibr">1991</xref>). All these effects lead to activation or inhibition of several downstream signals that contribute to the intrinsic effects of opioids (Stein, <xref rid="B101" ref-type="bibr">2016</xref>).</p></sec><sec id="s2"><title>Opioids and immune function</title><p>Opioids and their derivatives are the oldest and most effective drugs for treatment of pain (Lewis et al., <xref rid="B45" ref-type="bibr">1987</xref>). They are also one of the most popular recreational drugs and account for 27 million users worldwide (UNODC, <xref rid="B114" ref-type="bibr">2015</xref>). Opioid-mediated analgesia occurs through modulation of ascending and descending pain pathways (Kapitzke et al., <xref rid="B43" ref-type="bibr">2005</xref>). The immunomodulatory and anti-inflammatory properties of opioids have also been well documented (Bidlack, <xref rid="B6" ref-type="bibr">2000</xref>). Opioid receptors are abundantly expressed on various immune cells (e.g., lymphocytes, macrophages, neutrophils, and monocytes) and it has been shown that immune function is influenced by these receptors (Figure <xref ref-type="fig" rid="F1">1</xref>; McCarthy et al., <xref rid="B57" ref-type="bibr">2001</xref>; Odunayo et al., <xref rid="B66" ref-type="bibr">2010</xref>). It has been shown that immune cells contain opioid peptides such as &#946;-endorphin, metenkefalin, and dynorphin A, which have been proposed to alleviate inflammatory hyperalgesia (Kapitzke et al., <xref rid="B43" ref-type="bibr">2005</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p><bold>Opioid systems effects on immune responses</bold>. Opioid receptors are abundantly expressed on various immune cells and immune function is influenced by these receptors activation/inhibition. Numerous immune factors and immune responses are significantly dampened following opioid receptors activation. Opioid and chemokine receptors interaction on the immune cells surface regulates immune responses; Activation of opioid receptors by their ligands desensitizes chemokine receptors and also activation of chemokine receptor by its ligand desensitizes opioid receptor. Importantly, opioid receptors antagonists stimulates cellular immune responses and shifts immune responses to a Th1 pattern.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-07-00970-g0001.jpg"/></fig><p>Numerous immune factors and immune responses are significantly dampened following opioid exposure in drug users, healthy human subjects, and animal models (Rogers and Peterson, <xref rid="B77" ref-type="bibr">2003</xref>; Sacerdote, <xref rid="B82" ref-type="bibr">2006</xref>). These dampened immune functions include suppressed cytokine/chemokine production (Finley M. et al., <xref rid="B25" ref-type="bibr">2008</xref>), cytokine/chemokine receptors expression (Finley M. J. et al., <xref rid="B26" ref-type="bibr">2008</xref>), antibody production (Taub et al., <xref rid="B108" ref-type="bibr">1991</xref>), lymphocyte proliferation (McCarthy and Rogers, <xref rid="B56" ref-type="bibr">2001</xref>), NK cell activity (Shavit et al., <xref rid="B93" ref-type="bibr">1984</xref>), neutrophils function (Simpkins et al., <xref rid="B96" ref-type="bibr">1986</xref>), and macrophage phagocytic activity (Rojavin et al., <xref rid="B79" ref-type="bibr">1993</xref>). The activation of opioid receptors also induces apoptosis in immune cells (Singhal et al., <xref rid="B97" ref-type="bibr">1998</xref>); thus, endogenous/exogenous opioids, opioid receptors, and opioid signaling pathways together form a system (opioid system) which modulates immune function (Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>).</p><p>Opioid receptors and chemokine receptors and their ligands are widely expressed in brain tissue and immune cells (McCarthy et al., <xref rid="B57" ref-type="bibr">2001</xref>). Multiple lines of evidence have shown that interaction between opioids and chemokine receptors regulate immune responses (Steele et al., <xref rid="B100" ref-type="bibr">2002</xref>). Potential mechanisms for this interaction include heterologous desensitization (also known as cross-desensitization), changes in receptor expression, opioid and chemokine receptor dimerization or heteromerization, and regulation by the ferritin heavy chain (Rogers et al., <xref rid="B78" ref-type="bibr">2000</xref>; Nash and Meucci, <xref rid="B63" ref-type="bibr">2014</xref>). Activation of GPCRs such as opioids on the surface of immune cells often inhibits chemokine receptors by heterologous desensitization. The inhibitory crosstalk between opioids and chemokine receptors is believed to be a major element in regulation of the function of these receptors (Ali et al., <xref rid="B1" ref-type="bibr">1999</xref>; Rogers et al., <xref rid="B78" ref-type="bibr">2000</xref>). Several forms of desensitization occur between opioid and chemokine receptors. MOR and DOR are able to induce heterologous desensitization of CCR1, CCR2, CCR5, CXCR1, and CXCR2 (Grimm et al., <xref rid="B30" ref-type="bibr">1998</xref>). The CCR5 chemokine receptor can form heterodimers with the opioid receptors MOR, DOR, and KOR (Steele et al., <xref rid="B100" ref-type="bibr">2002</xref>; Szabo et al., <xref rid="B106" ref-type="bibr">2003</xref>; Chen et al., <xref rid="B12" ref-type="bibr">2004</xref>). KOR is able to cross-desensitize CXCR4 (Finley M. J. et al., <xref rid="B26" ref-type="bibr">2008</xref>) and ORL1 induces desensitization of CXCR4 (Kaminsky and Rogers, <xref rid="B42" ref-type="bibr">2011</xref>). Simultaneous stimulation of CXCR4 and DOR-expressing cells by their respective ligands, CXCL12 and DPDPE, does not trigger receptor function (Pello et al., <xref rid="B68" ref-type="bibr">2008</xref>). Opioid and CCR5/CXCR4 interaction potentially contribute to HIV-associated neurocognitive disorders (Steele et al., <xref rid="B99" ref-type="bibr">2003</xref>).</p><p>Importantly, besides immunomodulatory and anti-inflammatory activity, the opioid system could modulate T-helper (Th) cytokine patterns (Sacerdote et al., <xref rid="B84" ref-type="bibr">1998</xref>). Opioid receptor antagonists stimulate cellular immune responses and shifts immune responses to a Th1 pattern (Sacerdote et al., <xref rid="B83" ref-type="bibr">2000</xref>; Jazani et al., <xref rid="B41" ref-type="bibr">2011</xref>; Khorshidvand et al., <xref rid="B44" ref-type="bibr">2016</xref>). This ability to induce and shift immune responses toward a Th1 pattern makes opioid receptors antagonists as a new adjuvant candidate in the induction of cellular immunity which could increase protection against intracellular parasites (Khorshidvand et al., <xref rid="B44" ref-type="bibr">2016</xref>). These studies support the administration of opioid receptor blockers such as naloxone and/or naltrexone as a vaccine adjuvant to increase vaccine efficacy by enhancing cellular immunity (Jamali et al., <xref rid="B37" ref-type="bibr">2009</xref>; Jazani et al., <xref rid="B40" ref-type="bibr">2010</xref>, <xref rid="B41" ref-type="bibr">2011</xref>; Hajipirloo et al., <xref rid="B32" ref-type="bibr">2014</xref>; Shahabi et al., <xref rid="B91" ref-type="bibr">2014</xref>; Khorshidvand et al., <xref rid="B44" ref-type="bibr">2016</xref>). Taken together, the inhibition of anti-inflammatory and immunomodulatory activity of opioid signaling by opioid receptors antagonists explains the mechanisms by which opioid antagonists trigger vaccine-induced immunity (Khorshidvand et al., <xref rid="B44" ref-type="bibr">2016</xref>). Although many advances have been made in understanding the effects of opioids system on immune regulation, it is necessary to understand the real clinical relevance of this system (Ninkovic and Roy, <xref rid="B65" ref-type="bibr">2013</xref>).</p></sec><sec id="s3"><title>Opioids and viral infection</title><p>Although intensive research has rapidly advanced knowledge about the effect of the opioid system on immune function, little is known about the role of this system in the initiation and development of infection (Risdahl et al., <xref rid="B76" ref-type="bibr">1998</xref>). Through activation of opioid receptors, opioid systems effect diverse biological functions, including both innate and adoptive immune responses which can affect susceptibility to pathogens (Wang et al., <xref rid="B117" ref-type="bibr">2008</xref>). It is well documented that opioid abusers have a higher prevalence of opportunistic infections, which may be directly associated with impaired immune function (Roy et al., <xref rid="B81" ref-type="bibr">2011</xref>). Studies in healthy non-addicted individuals has revealed that opioid treatment in obstetrics results in reactivation of latent viruses, which can be directly explained by a dampened antiviral immune function (Crone et al., <xref rid="B18" ref-type="bibr">1988</xref>). A previous study by the authors indicates that endogenous opioids can control viral infection and could be useful for therapeutic applications (Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>).</p><p>Given the breadth of opioid-mediated signaling and immune regulation in mammals, the role of the opioid system has recently been highlighted in viral infections. The effects of opioids and their receptors have been studied for several viral infections (Table <xref ref-type="table" rid="T1">1</xref>). Opioid systems affect viral replication and pathogenesis in several ways (Figure <xref ref-type="fig" rid="F2">2</xref>). Interestingly, opioids have either a beneficial or deleterious effect on the pathogenesis of viruses directly through central nervous system (CNS) by their intrinsic immunomodulatory actions (Hu et al., <xref rid="B35" ref-type="bibr">2011</xref>). Depending on the virus type, activation of opioid receptors in immune and immune-associated cells directly or indirectly enhances (Wang C.-Q. et al., <xref rid="B116" ref-type="bibr">2005</xref>) or suppresses viral pathogenesis by modulating host immune responses (Coussons-Read et al., <xref rid="B17" ref-type="bibr">1999</xref>; Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>). Findings on the ability of opioids to modulate epigenetic mechanisms, in particular microRNAs (miRNAs) expression, shed new light on possible mechanisms underlying the effect of opioids on viral infection (Purohit et al., <xref rid="B75" ref-type="bibr">2012</xref>; Pilakka-Kanthikeel and Nair, <xref rid="B71" ref-type="bibr">2015</xref>). Furthermore, opioid interaction with viral receptors, viral proteins, and viral promoters effect viral replication during the course of an infection (Sundar et al., <xref rid="B105" ref-type="bibr">1996</xref>; Steele et al., <xref rid="B99" ref-type="bibr">2003</xref>; Chang and Connaghan, <xref rid="B8" ref-type="bibr">2012</xref>).</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p><bold>Opioid system effects on viral infections</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Viral infection</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Effects</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="20" colspan="1">HIV<break/><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmicb-07-00970-i0001.jpg"/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids impair the anti-HIV activity of immune system</td><td valign="top" align="left" rowspan="1" colspan="1">Wang X. et al., <xref rid="B119" ref-type="bibr">2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MORs activation up-regulates the CCR5 and CXCR4 expression</td><td valign="top" align="left" rowspan="1" colspan="1">Steele et al., <xref rid="B99" ref-type="bibr">2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids induce the pro-inflammatory mediators expression</td><td valign="top" align="left" rowspan="1" colspan="1">El-Hage et al., <xref rid="B24" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioid system disrupts the gut homeostasis</td><td valign="top" align="left" rowspan="1" colspan="1">Meng et al., <xref rid="B59" ref-type="bibr">2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids inhibit the anti-HIV miRNAs expression</td><td valign="top" align="left" rowspan="1" colspan="1">Wang et al., <xref rid="B120" ref-type="bibr">2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioid system reactivate the HIV latently infection</td><td valign="top" align="left" rowspan="1" colspan="1">Prottengeier et al., <xref rid="B72" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids induce the cytokine production and HIV promoter activation</td><td valign="top" align="left" rowspan="1" colspan="1">Sundar et al., <xref rid="B105" ref-type="bibr">1996</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine alters the &#946;-chemokines and CCR5 receptor expression</td><td valign="top" align="left" rowspan="1" colspan="1">Li et al., <xref rid="B46" ref-type="bibr">2003a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine limits the ability of neurons to recover from injury</td><td valign="top" align="left" rowspan="1" colspan="1">Masvekar et al., <xref rid="B54" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine promotes the growth of HIV in human PBMC</td><td valign="top" align="left" rowspan="1" colspan="1">Peterson et al., <xref rid="B70" ref-type="bibr">1990</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine exacerbates the neuropathogenesis process of HIV-1 gp 120</td><td valign="top" align="left" rowspan="1" colspan="1">Mahajan et al., <xref rid="B53" ref-type="bibr">2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine increases production of reactive free radical &amp; oxidative stress</td><td valign="top" align="left" rowspan="1" colspan="1">Turchan-Cholewo et al., <xref rid="B112" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KORs activation suppresses HIV-1 expression in infected microglial</td><td valign="top" align="left" rowspan="1" colspan="1">Chao et al., <xref rid="B10" ref-type="bibr">1996</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KORs activation suppresses HIV-1 expression in human brain cells</td><td valign="top" align="left" rowspan="1" colspan="1">Chao et al., <xref rid="B9" ref-type="bibr">1998</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KORs activation inhibits HIV-1 expression in infected CD4 cells</td><td valign="top" align="left" rowspan="1" colspan="1">Peterson et al., <xref rid="B69" ref-type="bibr">2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KORs activation reduces HIV-1 entry</td><td valign="top" align="left" rowspan="1" colspan="1">Lokensgard et al., <xref rid="B50" ref-type="bibr">2002</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DORs activation in T cells reduces the expression of HIV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Sharp et al., <xref rid="B92" ref-type="bibr">1998</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DORs activation attenuates Tat-induced intracellular oxidative stress</td><td valign="top" align="left" rowspan="1" colspan="1">Wallace et al., <xref rid="B115" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MORs activation reduces HIV-1 replication in TF-1 cells</td><td valign="top" align="left" rowspan="1" colspan="1">Strazza et al., <xref rid="B104" ref-type="bibr">2014</xref></td></tr><tr style="border-bottom: thin solid #000000;"><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Opioids suppress IL-16-induced signaling pathways</td><td valign="top" align="left" rowspan="1" colspan="1">Chao et al., <xref rid="B11" ref-type="bibr">1995</xref></td></tr><tr><td valign="middle" align="center" rowspan="10" colspan="1">HCV<break/><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmicb-07-00970-i0002.jpg"/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioid dependence therapy associates with lower incidence of HCV</td><td valign="top" align="left" rowspan="1" colspan="1">Tsui et al., <xref rid="B111" ref-type="bibr">2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine compromises anti-HCV effect of recombinant IFN-&#945;</td><td valign="top" align="left" rowspan="1" colspan="1">Li et al., <xref rid="B48" ref-type="bibr">2003b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine inhibits intracellular IFN-&#945; expression</td><td valign="top" align="left" rowspan="1" colspan="1">Li et al., <xref rid="B47" ref-type="bibr">2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine withdrawal inhibits expression of endogenous IFN-&#945;</td><td valign="top" align="left" rowspan="1" colspan="1">Wang C.-Q. et al., <xref rid="B116" ref-type="bibr">2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids impair CD56+ T cell-mediated innate immune function</td><td valign="top" align="left" rowspan="1" colspan="1">Ye et al., <xref rid="B125" ref-type="bibr">2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine induces hepatic pro-inflammatory cytokine and free radicals</td><td valign="top" align="left" rowspan="1" colspan="1">El-Hage et al., <xref rid="B23" ref-type="bibr">2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioid system synergize the alcohol acceleration of HCV expression</td><td valign="top" align="left" rowspan="1" colspan="1">Zhang et al., <xref rid="B128" ref-type="bibr">2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#946;-endorphins down-modulates T cell anti-bacterial response</td><td valign="top" align="left" rowspan="1" colspan="1">Amati et al., <xref rid="B3" ref-type="bibr">2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Met-enkephalin enhances replication of HCV and interferes with interferon</td><td valign="top" align="left" rowspan="1" colspan="1">Bergasa and Boyella, <xref rid="B5" ref-type="bibr">2008</xref></td></tr><tr style="border-bottom: thin solid #000000;"><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Met-enkephalin as a marker in hepatocellular damage in chronic HCV</td><td valign="top" align="left" rowspan="1" colspan="1">Ciesla et al., <xref rid="B15" ref-type="bibr">2006</xref></td></tr><tr><td valign="middle" align="center" rowspan="5" colspan="1">Influenza<break/><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmicb-07-00970-i0003.jpg"/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine impairs the inflammatory response to influenza in the lungs</td><td valign="top" align="left" rowspan="1" colspan="1">Hu et al., <xref rid="B35" ref-type="bibr">2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine treated rates slowly clear virus from their lungs</td><td valign="top" align="left" rowspan="1" colspan="1">Coussons-Read et al., <xref rid="B16" ref-type="bibr">1998</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioid system modulate NK cell cytotoxicity during influenza infection</td><td valign="top" align="left" rowspan="1" colspan="1">Tseng et al., <xref rid="B110" ref-type="bibr">2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opioids could increase risk of pneumonia after influenza as a consequent of immune suppression</td><td valign="top" align="left" rowspan="1" colspan="1">Dublin et al., <xref rid="B22" ref-type="bibr">2011</xref></td></tr><tr style="border-bottom: thin solid #000000;"><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Exposure to methadone significantly increased H1N1 viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">Chen et al., <xref rid="B13" ref-type="bibr">2015</xref></td></tr><tr><td valign="middle" align="center" rowspan="2" colspan="1">RSV<break/><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmicb-07-00970-i0004.jpg"/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">The A118G single nucleotide polymorphism rs1799971 associated with RSV disease severity</td><td valign="top" align="left" rowspan="1" colspan="1">Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref></td></tr><tr style="border-bottom: thin solid #000000;"><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Opioid system control RSV replication in the lung and consequently control virus immunopathogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref></td></tr><tr><td valign="middle" align="center" rowspan="14" colspan="1">HSV<break/><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmicb-07-00970-i0005.jpg"/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine alters innate immune responses against HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Sheridan and Moynihan, <xref rid="B94" ref-type="bibr">2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine diminishes protective innate immune defense against HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Jamali et al., <xref rid="B36" ref-type="bibr">2007a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine reduced CTL responses, lymphocyte proliferation, and IFN-&#947;</td><td valign="top" align="left" rowspan="1" colspan="1">Mojadadi et al., <xref rid="B60" ref-type="bibr">2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Withdrawal from morphine reduces protective immunity against HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Jamali et al., <xref rid="B39" ref-type="bibr">2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Endogenous opioids could suppress protective immunity against HSV-1</td><td valign="top" align="left" rowspan="1" colspan="1">Jamali et al., <xref rid="B38" ref-type="bibr">2007b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine treatment reduces HSV-1 mortality in infected mice</td><td valign="top" align="left" rowspan="1" colspan="1">Alonzo and Carr, <xref rid="B2" ref-type="bibr">1999</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine treatment reduces HSV-1 pathogenesis in infected mice</td><td valign="top" align="left" rowspan="1" colspan="1">Weeks et al., <xref rid="B122" ref-type="bibr">2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High incidence of HSV in patients given epidural morphine</td><td valign="top" align="left" rowspan="1" colspan="1">Gieraerts et al., <xref rid="B29" ref-type="bibr">1987</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epidural morphine reactivates oral herpes in the obstetric population</td><td valign="top" align="left" rowspan="1" colspan="1">Crone et al., <xref rid="B19" ref-type="bibr">1990</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Morphine potentiates development of encephalitis in HSV-1 infected mice</td><td valign="top" align="left" rowspan="1" colspan="1">Lioy et al., <xref rid="B49" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Attenuated hippocampal dynorphin causes seizures in HSV-1 infected rats</td><td valign="top" align="left" rowspan="1" colspan="1">Solbrig et al., <xref rid="B98" ref-type="bibr">2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MORs activation by loperamide suppress mechanical allodynia in mice with herpetic pain</td><td valign="top" align="left" rowspan="1" colspan="1">Sasaki et al., <xref rid="B89" ref-type="bibr">2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MORs activation by morphine suppress mechanical allodynia in mice with herpetic pain</td><td valign="top" align="left" rowspan="1" colspan="1">Sasaki et al., <xref rid="B90" ref-type="bibr">2008</xref></td></tr></tbody></table></table-wrap><fig id="F2" position="float" orientation="portrait"><label>Figure 2</label><caption><p><bold>Opioid systems effects on viral replication and pathogenesis</bold>. Opioids may positively or negatively affect the pathogenesis of viruses directly through the central nervous system (Hu et al., <xref rid="B35" ref-type="bibr">2011</xref>). Opioid receptors activation in immune and immune-associated cells directly or indirectly affect viral pathogenesis via modulating host immune responses (Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>). Modulation of epigenetic mechanisms such as miRNAs expression affect viral infection (Purohit et al., <xref rid="B75" ref-type="bibr">2012</xref>). Furthermore, interaction with several viral key factors such as viral receptors, viral proteins, and viral promoters may influence viral replication and virus-medicated pathology (Sundar et al., <xref rid="B105" ref-type="bibr">1996</xref>; Steele et al., <xref rid="B99" ref-type="bibr">2003</xref>; Chang and Connaghan, <xref rid="B8" ref-type="bibr">2012</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-07-00970-g0002.jpg"/></fig><p>The present study summarizes and discusses the effect of the opioid system on human viral infections, which are amongst the most important human pathogens. It is proposed that opioid system activity increases during viral infection and is involved in viral pathogenesis. Understanding the role of opioid system in viral infection is of importance for understanding disease pathogenesis and could lead to novel therapeutic approaches for viral infections.</p><sec><title>Human immunodeficiency virus</title><p>Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a serious cause of death in humans of all ages (Maartens et al., <xref rid="B52" ref-type="bibr">2014</xref>). Many HIV-infected subjects abuse morphine, heroin, or other opioid-related substances (Wang and Ho, <xref rid="B118" ref-type="bibr">2011</xref>). Nearly half of those problematic drug users inject drugs and an estimated 1.65 million of IV drug users were living with HIV in 2013 (UNODC, <xref rid="B114" ref-type="bibr">2015</xref>). Opioids have been suggested as promoting the pathogenesis of HIV in the CNS and exacerbating neurodegenerative diseases caused by chronic HIV (Hauser et al., <xref rid="B33" ref-type="bibr">2005</xref>). In addition, HIV-infected opioid abusers are at higher risk of developing HIV dementia (Turchan-Cholewo et al., <xref rid="B113" ref-type="bibr">2008</xref>). Importantly, accumulating evidence from <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies indicates that the opioid system can act as a cofactor in the immunopathogenesis of HIV, as they have the potential to impair host immune response and enhance microbial infections (Rouveix, <xref rid="B80" ref-type="bibr">1992</xref>). Several mechanisms have been proposed for the peripheral and neurotoxic effects of opioids in HIV infection, viral replication, and disease progression (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float" orientation="portrait"><label>Figure 3</label><caption><p><bold>Opioid systems effects on HIV replication and pathogenesis</bold>. Opioid system accelerate HIV pathogenesis and enhance susceptibility to HIV via several mechanisms. Opioid system impair the anti-HIV activity of immune system (Wang X. et al., <xref rid="B119" ref-type="bibr">2005</xref>), inhibit the expression of anti-HIV miRNAs (Wang et al., <xref rid="B120" ref-type="bibr">2011</xref>), induce the expression of several pro-inflammatory mediators (El-Hage et al., <xref rid="B24" ref-type="bibr">2006</xref>), up-regulate the expression of HIV-1 co-receptors (Steele et al., <xref rid="B99" ref-type="bibr">2003</xref>), disrupt gut homeostasis by modulating gastrointestinal motility and suppressing intestinal immune functions leading to enhanced gut bacterial translocation and disease progression during HIV infection (Meng et al., <xref rid="B59" ref-type="bibr">2015</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-07-00970-g0003.jpg"/></fig><p>The effect of opioids on the immune system plays an essential role in HIV peripheral and CNS pathogenesis. Opioid administration impairs the anti-HIV activity of the immune system which enhances HIV pathogenesis (Wang X. et al., <xref rid="B119" ref-type="bibr">2005</xref>). Activation of opioid receptors, especially MOR, up-regulates expression of the chemokine receptors CCR5 and CXCR4, two major HIV-1 entry co-receptors, which promotes HIV-1 replication (Steele et al., <xref rid="B99" ref-type="bibr">2003</xref>). Opioids induce expression of several pro-inflammatory mediators such as tumor necrosis factor-&#945; (TNF-&#945;), interleukin (IL)-6, and CCL5 and accelerates HIV neuropathogenesis (El-Hage et al., <xref rid="B24" ref-type="bibr">2006</xref>). Opioids have been shown to disrupt gut homeostasis by modulating gastrointestinal motility and suppressing intestinal immune functions elevating gut bacterial translocation, which activates the immune system and accelerates disease progression during HIV infection (Meng et al., <xref rid="B59" ref-type="bibr">2015</xref>). Endogenous opioids, as do exogenous opioids, can potentiate HIV-1 replication by inducing cytokine production and stimulation of HIV promoter (Sundar et al., <xref rid="B105" ref-type="bibr">1996</xref>).</p><p>Morphine is a widely-used opioid that accelerates HIV peripheral pathogenesis in several ways. Morphine treatment enhances susceptibility of neonatal monocyte-derived macrophages to HIV infection most likely through alteration of &#946;-chemokines and CCR5 receptor expression (Li et al., <xref rid="B46" ref-type="bibr">2003a</xref>). Morphine promotes growth of HIV-1 in human peripheral blood mononuclear cells by altering the function of human T lymphocytes and monocytes (Peterson et al., <xref rid="B70" ref-type="bibr">1990</xref>). Furthermore, HIV-1 gp120 primes lymphocytes for morphine-mediated apoptosis (Moorman et al., <xref rid="B61" ref-type="bibr">2009</xref>).</p><p>While the opioid system can act as a cofactor in the pathogenesis of HIV, in some instances it can also inhibit HIV expression. Chao et al. reported that activation of KORs suppresses HIV-1 expression in infected microglial (Chao et al., <xref rid="B10" ref-type="bibr">1996</xref>) and in human brain cells by potentiation of TNF-&#945; (Chao et al., <xref rid="B9" ref-type="bibr">1998</xref>). Activation of KORs inhibits expression of HIV-1 in infected CD4 lymphocyte cultures (Peterson et al., <xref rid="B69" ref-type="bibr">2001</xref>) and reduces HIV-1 entry through inhibition of envelope gp-mediated membrane fusion and CXCR4 expression (Lokensgard et al., <xref rid="B50" ref-type="bibr">2002</xref>). Sharp et al. have shown that activation of DORs in T cells reduces the expression of HIV-1. Activation of DORs affects intracellular signaling that is known to mediate CD4 T cell activation and expression of HIV-1 (Sharp et al., <xref rid="B92" ref-type="bibr">1998</xref>). DOR activation also attenuates Tat-induced intracellular oxidative stress in SK-N-SH cells (Wallace et al., <xref rid="B115" ref-type="bibr">2006</xref>). Strazza et al. stated that MOR activation by DAMGO alters expression of CXCR4 and reduces HIV-1 replication in TF-1 human bone marrow progenitor cells (Strazza et al., <xref rid="B104" ref-type="bibr">2014</xref>). Furthermore, opioids suppress IL-16-induced signaling pathways, which in turn inhibit HIV-1 expression in chronically infected promonocyte clone 1 (Chao et al., <xref rid="B11" ref-type="bibr">1995</xref>).</p><p>The effect of opioids on epigenetics, especially miRNA expression, could affect HIV replication and pathogenesis. For example, the opioid system inhibits expression of anti-HIV miRNAs (e.g., miRNA-28, 125b, 150, and 382) that target 3&#8242;-UTR of HIV transcripts (Wang et al., <xref rid="B120" ref-type="bibr">2011</xref>). Interestingly, Purohit et al. found that down-regulation or inhibition of the activity of this miRNA can stimulate replication of latent HIV-1 in resting CD4<sup>+</sup> T cells and monocytes (Purohit et al., <xref rid="B75" ref-type="bibr">2012</xref>). Opioids also reactivate latent HIV infections <italic toggle="yes">in vitro</italic> which is associated with activation of reactive oxygen species (ROS) and nuclear factor-kappa B (NF-&#954;B) (Prottengeier et al., <xref rid="B72" ref-type="bibr">2014</xref>).</p><p>Differential expression of alternatively-spliced opioid receptor isoforms and polymorphisms in HIV-infected subjects could affect the pathophysiology of HIV infection (Dever et al., <xref rid="B21" ref-type="bibr">2014</xref>). Proudnikov et al. showed that OPRM1 polymorphism alters the severity of HIV infection before and after HAART (Proudnikov et al., <xref rid="B73" ref-type="bibr">2012</xref>). They also revealed that OPRK1 and PDYN polymorphism alters the severity of HIV infection and response to treatment (Proudnikov et al., <xref rid="B74" ref-type="bibr">2013</xref>).</p><p>Morphine increases neurotoxic effects of HIV, and also limits the ability of neurons to recover from sublethal damage (Masvekar et al., <xref rid="B54" ref-type="bibr">2014</xref>). Also, morphine synergizes the toxic effect of HIV proteins. For example morphine exacerbates neuropathogenesis of HIV-1 glycoprotein (gp) 120 by altering the chemokine balance in the brain (Mahajan et al., <xref rid="B53" ref-type="bibr">2005</xref>). Importantly, HIV-1 gp120 and morphine cooperatively induce oxidative stress and affect cell cycle machinery, which may cause disease progression (Samikkannu et al., <xref rid="B88" ref-type="bibr">2015</xref>). The interaction of the HIV-1 transactivator of transcription (Tat) and morphine increases the neurodegenerative effects through MORs signaling (Zou et al., <xref rid="B129" ref-type="bibr">2011</xref>).</p><p>Turchan-Cholewo et al. showed that Tat and morphine synergistically increase the production of ROS (Turchan-Cholewo et al., <xref rid="B112" ref-type="bibr">2009</xref>). HIV-Tat triggers opioid signaling in the microglia through induction of receptor expression or alters ligand-induced trafficking of opioid receptors (Turchan-Cholewo et al., <xref rid="B113" ref-type="bibr">2008</xref>). Therapeutic interventions that target the opioid system could be targeted to mitigate neuropathogenesis and neuroAIDS. For example, Sagar et al. demonstrated that using a novel therapeutic approach (neurotargeting via magnetic nanocarrier) could be effective in targeting opiate-induced neuropathogenesis and neuroAIDS (Sagar et al., <xref rid="B85" ref-type="bibr">2015</xref>). Yuan et al. suggested that a properly designed bivalent ligand targeting the putative MOR and CCR5 heterodimers could block HIV invasion into host cells by specifically targeting the putative MOR-CCR5 heterodimer (Yuan et al., <xref rid="B126" ref-type="bibr">2013</xref>).</p><p>The data indicates that opioid systems have a significant effect on HIV infection, pathogenesis, and immune regulation. Mechanisms associated with enhancement of HIV pathogenesis through the opioid system appear to work through activation of opioid receptors and their downstream signaling pathways to make them possible targets for therapeutic intervention in HIV infection.</p></sec><sec><title>Hepatitis C virus</title><p>The hepatitis C virus (HCV) causes severe liver disorders such as fibrosis, cirrhosis, and cancer (Webster et al., <xref rid="B121" ref-type="bibr">2015</xref>). HCV prevalence is high among opioid-dependent individuals (range 10&#8211;90% in different region; UNODC, <xref rid="B114" ref-type="bibr">2015</xref>), and HCV-related disorders are common causes of morbidity and mortality in opioid users (Gibson et al., <xref rid="B28" ref-type="bibr">2011</xref>; Nelson et al., <xref rid="B64" ref-type="bibr">2011</xref>). Opioid users are exposed to needle sharing, unsafe disposal and unsuitable cleaning of needles, as well as unsafe sex, which make them prone to HCV infection (Hagan et al., <xref rid="B31" ref-type="bibr">2001</xref>). Maintenance of opioid agonist therapy (methadone or buprenorphine) in opioid users is associated with lower incidence of HCV, which may be an important strategy for prevention of the spread of HCV among drug users (Tsui et al., <xref rid="B111" ref-type="bibr">2014</xref>). Furthermore, simultaneous targeting of HCV infection and opioid dependence has been shown to be effective for drug users infected with HCV (Murphy et al., <xref rid="B62" ref-type="bibr">2014</xref>). Despite the high prevalence of HCV in opioid users, little is known about molecular mechanisms contributing to HCV infection among opioid-dependent individuals.</p><p>Chronic opioid abuse has a severe negative impact on the immune system (Figure <xref ref-type="fig" rid="F4">4</xref>). The negative impact of opioids on host immunity in an important factor in the development of acute and chronic HCV infections (Zhang et al., <xref rid="B127" ref-type="bibr">2006</xref>). <italic toggle="yes">In vitro</italic> investigations indicate that opioids facilitate HCV infection in hepatocytes by suppressing interferon (IFN)-&#945;-mediated intracellular innate immunity (Li et al., <xref rid="B48" ref-type="bibr">2003b</xref>, <xref rid="B47" ref-type="bibr">2007</xref>; Wang C.-Q. et al., <xref rid="B116" ref-type="bibr">2005</xref>). Li et al. demonstrated that morphine compromised the anti-HCV effect of recombinant IFN-&#945; augmenting HCV replicon expression in hepatic cells (Li et al., <xref rid="B48" ref-type="bibr">2003b</xref>). They revealed that morphine inhibited intracellular IFN-&#945; expression in newly-infectious infected cells, which further facilitates HCV persistence in human hepatocytes (Li et al., <xref rid="B47" ref-type="bibr">2007</xref>). Wang et al. reported that morphine withdrawal, a recurrent event during the course of opioid abuse, inhibits expression of endogenous IFN-&#945; and enhances HCV replicon expression in hepatic cells (Wang C.-Q. et al., <xref rid="B116" ref-type="bibr">2005</xref>). Morphine inhibits IFN-&#945; by direct interaction with IFN-&#945; promoter and interferon regulatory factors (IRF)-5, IRF-7, and p38 (Li et al., <xref rid="B48" ref-type="bibr">2003b</xref>, <xref rid="B47" ref-type="bibr">2007</xref>; Wang C.-Q. et al., <xref rid="B116" ref-type="bibr">2005</xref>). These important <italic toggle="yes">in vitro</italic> findings were confirmed by Ye et al., who demonstrated that administration of opioids results in impairment of CD56<sup>+</sup> T cell-mediated innate immune function (secretion of IFN-&#947;) through up-regulation of cytokine signaling 3 and protein inhibition of activated STAT 3 (SOCS-3), which may contribute to HCV infection and persistence in the liver (Ye et al., <xref rid="B125" ref-type="bibr">2010</xref>).</p><fig id="F4" position="float" orientation="portrait"><label>Figure 4</label><caption><p><bold>Opioid systems effects on HCV replication and pathogenesis</bold>. Opioid systems accelerate HCV pathogenesis and enhance susceptibility to HCV infection via several mechanisms. Opioid system impair the expression of IFN-&#945; (Li et al., <xref rid="B47" ref-type="bibr">2007</xref>), and IFN-&#947; (Ye et al., <xref rid="B125" ref-type="bibr">2010</xref>), and also down-regulate the T cell anti-bacterial response in HCV patients by activation of opioid receptors in immune cells, which accelerates disease progression (Amati et al., <xref rid="B3" ref-type="bibr">2001</xref>). Opioids also induce the expression of ROS and NO leading to disease progression (El-Hage et al., <xref rid="B23" ref-type="bibr">2011</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-07-00970-g0004.jpg"/></fig><p>Opioid-induced oxidative damage has been assumed to contribute to many of the systemic signs of liver disorder and toxicity as illustrated in mice as well as opioid abusers (Tennant and Moll, <xref rid="B109" ref-type="bibr">1995</xref>; Payabvash et al., <xref rid="B67" ref-type="bibr">2006</xref>). El-Hage et al. have shown that morphine accelerates HCV-mediated pathology by dysregulation of HCV-induced hepatic pro-inflammatory cytokines expression such as TNF-&#945; and CCL5 and free radical production such as ROS and nitric oxide (NO) in HCV JFH1-infected hepatocytes (El-Hage et al., <xref rid="B23" ref-type="bibr">2011</xref>). Furthermore, opioid system synergizes with the effect of alcohol to accelerate HCV replication, because enhancement of the effect of alcohol on HCV replicon expression was abrogated following administration of naltrexone as an opioid receptor antagonist (Zhang et al., <xref rid="B128" ref-type="bibr">2003</xref>).</p><p>Endogenous opioids, like exogenous opioids, act as cofactors in HCV replication and pathogenesis. For example, &#946;-endorphins down-modulate T cell anti-bacterial response in HCV patients by activation of opioid receptors in immune cells (Amati et al., <xref rid="B3" ref-type="bibr">2001</xref>). The met-enkephalin concentration is high in the liver of HCV patients and is a useful marker of hepatocellular damage in chronic HCV (Ciesla et al., <xref rid="B15" ref-type="bibr">2006</xref>). Met-enkephalin activates MORs and DORs which enhance replication of HCV in hepatic cells (Bergasa and Boyella, <xref rid="B5" ref-type="bibr">2008</xref>), particularly in the liver of HCV patients (Boyella et al., <xref rid="B7" ref-type="bibr">2008</xref>), and also interferes with the anti-viral effect of type I interferon (Floreani et al., <xref rid="B27" ref-type="bibr">2012</xref>). The low efficiency of interferon therapy for HCV treatment in some patients could be explained by the effects of hepatic met-enkephalins (Bergasa and Boyella, <xref rid="B5" ref-type="bibr">2008</xref>; Boyella et al., <xref rid="B7" ref-type="bibr">2008</xref>).</p><p>Taken together, these results suggest that opioids accelerate HCV pathogenesis and establish chronic HCV infection, especially in drug abusers. Further consideration should be given to opioid abuse as a contributing factor for the increase in HCV infection among opioid-dependent individuals. Better understanding of the relationship between HCV and the opioid system may yield new therapeutic intervention in HCV carriers.</p></sec><sec><title>Influenza virus</title><p>Opioid systems effect infections caused by HIV and HCV, but little is known about the role of opioid systems in the pathogenesis of other clinically important viral pathogens. Evaluating the effects of the opioid system on influenza infection could provide valuable information as it is a serious public health. Influenza causes viral respiratory tract diseases ranging from mild upper respiratory infection to severe pneumonia (Short et al., <xref rid="B95" ref-type="bibr">2014</xref>). When airway epithelial cells are infected by the influenza virus, infiltration of various immune cells occurs. It is known that infiltrating immune cells are directed against infected epithelial cells, causing immunopathogenesis (Tahamtan et al., <xref rid="B107" ref-type="bibr">2016</xref>).</p><p>Because opioids alter immune function, it is likely that this system also effects the immunopathogenesis of influenza in the pulmonary tract (Figure <xref ref-type="fig" rid="F5">5</xref>). Coussons-Read et al. examined the effect of morphine treatment on pulmonary inflammatory response to intranasal influenza infection in Lewis rats (Coussons-Read et al., <xref rid="B17" ref-type="bibr">1999</xref>). They show that morphine impairs the inflammatory response to influenza infection in the lung by prevention of inflammatory cells in the lung, lowering the percentage of polymorphonuclear cells in the bronchoalveolar lavage fluid (BALF), decreasing the protein and lactate dehydrogenase content in BALF, and reducing the wet weight of the lung (Coussons-Read et al., <xref rid="B17" ref-type="bibr">1999</xref>). They also revealed that the influenza virus cleared slowly from the lungs of morphine-treated rats compared to non-treated and placebo controls, suggesting that there may be a relationship between impaired inflammatory response and viral clearance (Coussons-Read et al., <xref rid="B16" ref-type="bibr">1998</xref>).</p><fig id="F5" position="float" orientation="portrait"><label>Figure 5</label><caption><p><bold>Opioid systems effects on influenza/RSV immunopathogenesis</bold>. Opioids may attenuate immunopathogenesis of influenza and RSV via immunomodulatory and anti-inflammatory actions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-07-00970-g0005.jpg"/></fig><p>Tseng et al. revealed that opioid systems activate MORs which modulate NK cell cytotoxicity during influenza infection (Tseng et al., <xref rid="B110" ref-type="bibr">2005</xref>). Importantly, opioids could increase the risk of pneumonia after influenza as a consequence of immune suppression function (Dublin et al., <xref rid="B22" ref-type="bibr">2011</xref>). Chen et al. showed that exposure to methadone significantly increased H1N1 viral replication in lungs, which might increase the augmented risk of serious influenza A virus infection in people who receive opioid-dependence therapy (Chen et al., <xref rid="B13" ref-type="bibr">2015</xref>).</p><p>These results suggest that the opioid systems impair or modulate immune responses induced by the influenza virus that might be beneficial for controlling viral immunopathogenesis, but may lead to delayed viral clearance. Although the data clearly show that opioid system alters the pulmonary inflammatory response to influenza infection, the mechanism of these effects remains unclear. An important step in understanding the role opioids play in pulmonary immune status is unraveling the underlying mechanism of the effects of opioid system on pulmonary inflammation.</p></sec><sec><title>Respiratory syncytial virus</title><p>Respiratory syncytial virus (RSV) causes severe respiratory disease and even death in neonates and the elderly (Lozano et al., <xref rid="B51" ref-type="bibr">2012</xref>; Salimi et al., <xref rid="B87" ref-type="bibr">2016</xref>). RSV infections such as influenza causes infiltration of immune cells by infected epithelial cells, which causes immunopathology (Stoppelenburg et al., <xref rid="B103" ref-type="bibr">2013</xref>). Opioids are frequently used during mechanical ventilation of severe RSV infection and some studies have examined the effects of opioids and their receptors on RSV infection. A human study and an experimental model by the authors recently demonstrated opioid system control of RSV replication in the lung and of virus-induced pathology (Figure <xref ref-type="fig" rid="F5">5</xref>). In the human study, A118G single nucleotide polymorphism rs1799971 in the OPRM1 gene was found to be associated with RSV disease severity. Cases with G alleles are less prone to develop severe RSV infection than those with A alleles (Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>). A single nucleotide polymorphism at position 118 in the coding region of the OPRM1 alters immune response and prevents secretion of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-&#945; (Matsunaga et al., <xref rid="B55" ref-type="bibr">2009</xref>). In mice, administration of the opioid receptor antagonist nalmefene increased RSV viral load and is associated with increased levels of cytokines and chemokines in the BALF, enhanced bronchoalveolar cellular influx, and exaggerated lung pathology. It was also demonstrated that activation of opioid receptors using &#956; (DAMGO), &#954; (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="U50488">U50488</ext-link>), and &#948; (DPDPE) agonists reduced neutrophil influx (Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>).</p><p>Taken together, these results suggested that opioid systems have a beneficial role in the outcome of respiratory viral disease and could serve as effective therapeutic targets. Opioid receptor activation could offer powerful novel pharmacologic targets to amend RSV-induced immunopathogenesis, although the clinical effects of pharmaceutical agonists should be evaluated.</p></sec><sec><title>Herpes simplex virus</title><p>Herpes simplex viruses (HSVs) are a worldwide infectious agents causing variety of diseases such as oral and genital lesions, encephalitis, neonatal infections, and tumors (Whitley and Roizman, <xref rid="B123" ref-type="bibr">2001</xref>). Opioids administration is known to affect the course of HSV infection because of their immunosuppressive function. For example, morphine, a broadly studied and widely used opioid, is known to alter HSV infection, immune response, as well as latency (Jamali et al., <xref rid="B36" ref-type="bibr">2007a</xref>, <xref rid="B39" ref-type="bibr">2012</xref>; Mojadadi et al., <xref rid="B60" ref-type="bibr">2009</xref>; Bauchat, <xref rid="B4" ref-type="bibr">2010</xref>).</p><p>It has been clearly demonstrated that morphine alters innate immune responses, which affect the ability of an infected host to mount a specific immune response and clear HSV-1 (Sheridan and Moynihan, <xref rid="B94" ref-type="bibr">2005</xref>). Acute morphine administration diminishes the ability of white blood cells to induce a protective innate immune defense against HSV-1 infection through inhibition of IFN-&#947; production and NK cell activity (Jamali et al., <xref rid="B36" ref-type="bibr">2007a</xref>). Mojadadi et al. found that acute morphine administration significantly reduced cytolytic T lymphocyte response, lymphocyte proliferation, and IFN-&#947; production, which consequently reactivated HSV-1 latency in BALB/c mice (Mojadadi et al., <xref rid="B60" ref-type="bibr">2009</xref>). Cellular immune response plays an important role in the inhibition of HSV reactivation and withdrawal from morphine has been shown to reduce protective immunity against acute HSV-1 (Jamali et al., <xref rid="B39" ref-type="bibr">2012</xref>). Endogenous opioids suppress protective immunity against primary HSV-1 infection (Jamali et al., <xref rid="B38" ref-type="bibr">2007b</xref>). Paradoxically, morphine treatment reduced HSV-1-mediated pathology in infected mice by alleviating some of the unwarranted immunopathological manifestations associated with these infections, but not by reducing the viral replication rate (Alonzo and Carr, <xref rid="B2" ref-type="bibr">1999</xref>; Weeks et al., <xref rid="B122" ref-type="bibr">2001</xref>).</p><p>Given the immunosuppressive effects of opioids, it has been demonstrated that morphine reactivates latent HSV (Davies et al., <xref rid="B20" ref-type="bibr">2005</xref>). Gieraerts et al. reported high prevalence of HSV infection in patients receiving epidural morphine following cesarean section (Gieraerts et al., <xref rid="B29" ref-type="bibr">1987</xref>). A significant association between the use of epidural morphine which is commonly used for postoperative analgesia after cesarean section and reactivation of oral herpes in the obstetric population has also been reported (Crone et al., <xref rid="B19" ref-type="bibr">1990</xref>).</p><p>Acute morphine administration potentiates the development of encephalitis in HSV-1 infected mice (Lioy et al., <xref rid="B49" ref-type="bibr">2006</xref>). In this regard morphine exposure decreases integrity of the blood-brain barrier (BBB) and might explain its potential role for involvement of BBB in the development of encephalitis in morphine-treated mice (Lioy et al., <xref rid="B49" ref-type="bibr">2006</xref>). It has been shown that a hippocampal dynorphin system causes seizures in HSV-1 infected rats. Dynorphin is the preferred endogenous opioid for KOR activation with broad homeostatic functions (Solbrig et al., <xref rid="B98" ref-type="bibr">2006</xref>). Furthermore, activation of peripheral MORs by morphine and loperamide suppresses mechanical allodynia in mice with herpetic pain (Sasaki et al., <xref rid="B89" ref-type="bibr">2007</xref>, <xref rid="B90" ref-type="bibr">2008</xref>).</p><p>Altogether, these findings indicate that opioid systems suppress protective immunity against HSV infection and induce HSV reactivation. More extensive studies are required to explore the role of opioid system in HSV and other herpes viruses such as EBV and CMV infection for more efficient therapeutic approaches.</p></sec></sec><sec sec-type="conclusions" id="s4"><title>Conclusion</title><p>In recent years, data the opioid system has received attention because it demonstrates the influence on immune cells and immune function. In addition, there is a large body of evidence from <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> models indicating that opioid systems effect viral replication and virus-mediated pathology. The diverse effects of the opioid system on viral infection imply involvement of different mechanisms. The effect of opioids on immune cells, epigenetics, viral, and cellular factors are implicated in the pathogenesis. For the majority of viruses, opioid system enhances viral pathogenesis by modulation of immune responses (Sheridan and Moynihan, <xref rid="B94" ref-type="bibr">2005</xref>; Wang X. et al., <xref rid="B119" ref-type="bibr">2005</xref>; Zhang et al., <xref rid="B127" ref-type="bibr">2006</xref>). Accordingly, blockage of opioid receptors can potentially be applied for viral control. On the other hand, activation of opioid receptors is beneficial for controlling viral pathogenesis in those viral infections where host immune responses are pathogenic (Coussons-Read et al., <xref rid="B17" ref-type="bibr">1999</xref>; Salimi et al., <xref rid="B86" ref-type="bibr">2013</xref>).</p><p>Exploring the interplay between viruses and opioid system and corresponding molecular mechanisms is an important tool for understanding the effect of opioids, mechanisms of action, and development of therapeutic strategies. Clearly more work needs to be done, especially in clinical settings, to promote the importance of understanding the exact interaction between opioid system and viral infections. Because endogenous opioid systems have favorable functions, manipulation of these systems should be performed with caution. To investigate this interaction, further research is required in the following areas:
<list list-type="bullet"><list-item><p>While opioids and their receptors are involved in the pathogenesis of several viral infections, the exact mechanisms remain unknown. For example, the signaling pathways between opioids and viruses require further investigation.</p></list-item><list-item><p>Although the <italic toggle="yes">in vitro</italic> and animal model effects of opioids are well documented, few have explored the effect of opioids on viral infection in clinical settings and future studies with a larger sample sizes are necessary to determine the opioid system effects.</p></list-item><list-item><p>Initial data indicates a beneficial role of opioids in the outcome of respiratory viral diseases. Novel essential therapeutic approaches based on opioid system activation and/or inhibition are required for full characterization.</p></list-item></list></p></sec><sec id="s5"><title>Author contributions</title><p>Conceived and designed: AT, MT-Y, VS. Analyzed the data: AT, MT-Y, TM, VS. Wrote the paper: AT, MT-Y, TM, MT-R, LB, FS, VS. Helpful discussions and critical review of the manuscript: TM, LB, FS.</p></sec><sec><title>Funding</title><p>This work was partially supported by the School of Public Health, Tehran University of Medical Sciences (28054) and University Medical Centre Utrecht (R1763). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>H.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Haribabu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Snyderman</surname><given-names>R.</given-names></name></person-group> (<year>1999</year>). <article-title>Chemoattractant receptor cross-desensitization</article-title>. <source>J. Biol. Chem.</source><volume>274</volume>, <fpage>6027</fpage>&#8211;<lpage>6030</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.10.6027</pub-id><pub-id pub-id-type="pmid">10037679</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonzo</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Morphine reduces mortality in mice following ocular infection with HSV-1</article-title>. <source>Immunopharmacology</source><volume>41</volume>, <fpage>187</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/S0162-3109(99)00003-X</pub-id><pub-id pub-id-type="pmid">10428647</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caradonna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Magrone</surname><given-names>T.</given-names></name><name name-style="western"><surname>Manghisi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leandro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Caccavo</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title><italic toggle="yes">In vitro</italic> effects of naloxone on T-lymphocyte-dependent antibacterial activity in hepatitis C virus (HCV) infected patients and in inflammatory bowel disease (IBD) patients</article-title>. <source>Immunopharmacol. Immunotoxicol.</source><volume>23</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1081/IPH-100102562</pub-id><pub-id pub-id-type="pmid">11322642</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauchat</surname><given-names>J. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuraxial morphine and oral herpes reactivation in the obstetric population</article-title>. <source>Anesth. Analg.</source><volume>111</volume>, <fpage>1238</fpage>&#8211;<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0b013e3181f57c30</pub-id><pub-id pub-id-type="pmid">20881282</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergasa</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Boyella</surname><given-names>V. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Liver derived endogenous opioids may interfere with the therapeutic effect of interferon in chronic hepatitis C</article-title>. <source>Med. Hypotheses</source><volume>70</volume>, <fpage>556</fpage>&#8211;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2007.06.022</pub-id><pub-id pub-id-type="pmid">17692472</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bidlack</surname><given-names>J. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Detection and function of opioid receptors on cells from the immune system</article-title>. <source>Clin. Diagn. Lab. Immunol.</source><volume>7</volume>, <fpage>719</fpage>&#8211;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1128/cdli.7.5.719-723.2000</pub-id><pub-id pub-id-type="pmid">10973443</pub-id><pub-id pub-id-type="pmcid">PMC95944</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyella</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Nicastri</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Bergasa</surname><given-names>N. V.</given-names></name></person-group> (<year>2008</year>). <article-title>Human hepatic met-enkephalin and delta opioid receptor-1 immunoreactivities in viral and autoimmune hepatitis</article-title>. <source>Ann. Hepatol.</source><volume>7</volume>, <fpage>221</fpage>&#8211;<lpage>226</lpage>. <pub-id pub-id-type="pmid">18753988</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Connaghan</surname><given-names>K. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Behavioral and molecular evidence for a feedback interaction between morphine and HIV-1 viral proteins</article-title>. <source>J. Neuroimmune Pharmacol.</source><volume>7</volume>, <fpage>332</fpage>&#8211;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9324-1</pub-id><pub-id pub-id-type="pmid">22083500</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kravitz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>1998</year>). <article-title>&#954;-opioid potentiation of tumor necrosis factor-&#945;-induced anti-HIV-1 activity in acutely infected human brain cell cultures</article-title>. <source>Biochem. Pharmacol.</source><volume>56</volume>, <fpage>397</fpage>&#8211;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(98)00161-0</pub-id><pub-id pub-id-type="pmid">9744578</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Shark</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>D. F.</given-names></name><etal/></person-group>. (<year>1996</year>). <article-title>kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>93</volume>, <fpage>8051</fpage>&#8211;<lpage>8056</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.93.15.8051</pub-id><pub-id pub-id-type="pmid">8755601</pub-id><pub-id pub-id-type="pmcid">PMC38873</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Portoghese</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>1995</year>). <article-title>Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1</article-title>. <source>Adv. Exp. Med. Biol.</source><volume>373</volume>, <fpage>65</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-1951-5_10</pub-id><pub-id pub-id-type="pmid">7668162</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bot</surname><given-names>G.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Liu-Chen</surname><given-names>L.-Y.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Heterodimerization and cross-desensitization between the &#956;-opioid receptor and the chemokine CCR5 receptor</article-title>. <source>Eur. J. Pharmacol.</source><volume>483</volume>, <fpage>175</fpage>&#8211;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2003.10.033</pub-id><pub-id pub-id-type="pmid">14729105</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Methadone enhances human influenza A virus replication</article-title>. <source>Addict. Biol.</source><pub-id pub-id-type="doi">10.1111/adb.12305</pub-id>. [Epub ahead of print].<pub-id pub-id-type="pmid">26350582</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Childers</surname><given-names>S. R.</given-names></name></person-group> (<year>1991</year>). <article-title>Opioid receptor-coupled second messenger systems</article-title>. <source>Life Sci.</source><volume>48</volume>, <fpage>1991</fpage>&#8211;<lpage>2003</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(91)90154-4</pub-id><pub-id pub-id-type="pmid">1851914</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciesla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pierzchala-Koziec</surname><given-names>K.</given-names></name><name name-style="western"><surname>Skwara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szczepanski</surname><given-names>W.</given-names></name></person-group> (<year>2006</year>). <article-title>Met-enkephalin in the liver as a marker of hepatocellular damage in chronic viral hepatitis type B and C</article-title>. <source>Adv. Med. Sci.</source><volume>51</volume>, <fpage>261</fpage>&#8211;<lpage>264</lpage>. <pub-id pub-id-type="pmid">17357322</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coussons-Read</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gilmour</surname><given-names>M. I.</given-names></name></person-group> (<year>1998</year>). <article-title>Morphine alters the immune response to influenza virus infection in Lewis rats</article-title>. <source>Adv. Exp. Med. Biol.</source><volume>437</volume>, <fpage>73</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-5347-2_9</pub-id><pub-id pub-id-type="pmid">9666259</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coussons-Read</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gilmour</surname><given-names>M. I.</given-names></name></person-group> (<year>1999</year>). <article-title>Morphine reduces pulmonary inflammation in response to influenza infection</article-title>. <source>Life Sci.</source><volume>65</volume>, <fpage>1141</fpage>&#8211;<lpage>1152</lpage>. <pub-id pub-id-type="doi">10.1016/S0024-3205(99)00348-3</pub-id><pub-id pub-id-type="pmid">10503930</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crone</surname><given-names>L.-A.</given-names></name><name name-style="western"><surname>Conly</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Crichlow</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Wardell</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Zbitnew</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>1988</year>). <article-title>Recurrent herpes simplex virus labialis and the use of epidural morphine in obstetric patients</article-title>. <source>Anesth. Analg.</source><volume>67</volume>, <fpage>318</fpage>&#8211;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1213/00000539-198804000-00004</pub-id><pub-id pub-id-type="pmid">3354864</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crone</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Conly</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Storgard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zbitnew</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cronk</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Rea</surname><given-names>L. M.</given-names></name><etal/></person-group>. (<year>1990</year>). <article-title>Herpes labialis in parturients receiving epidural morphine following cesarean section</article-title>. <source>Anesthesiology</source><volume>73</volume>, <fpage>208</fpage>&#8211;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1097/00000542-199008000-00003</pub-id><pub-id pub-id-type="pmid">2166452</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Vallejo</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Amortegui</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Oral herpes simplex reactivation after intrathecal morphine: a prospective randomized trial in an obstetric population</article-title>. <source>Anesth. Analg.</source><volume>100</volume>, <fpage>1472</fpage>&#8211;<lpage>1476</lpage>. <pub-id pub-id-type="doi">10.1213/01.ANE.0000153013.34129.A7</pub-id><pub-id pub-id-type="pmid">15845709</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dever</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Costin</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Balinang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samoshkin</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Differential expression of the alternatively spliced OPRM1 isoform &#956;-opioid receptor-1K in HIV-infected individuals</article-title>. <source>AIDS</source><volume>28</volume>, <fpage>19</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000000113</pub-id><pub-id pub-id-type="pmid">24413261</pub-id><pub-id pub-id-type="pmcid">PMC3939043</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dublin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>N. S.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case&#8211;control study</article-title>. <source>J. Am. Geriatr. Soc.</source><volume>59</volume>, <fpage>1899</fpage>&#8211;<lpage>1907</lpage>. <pub-id pub-id-type="doi">10.1111/j.1532-5415.2011.03586.x</pub-id><pub-id pub-id-type="pmid">22091503</pub-id><pub-id pub-id-type="pmcid">PMC3223721</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dever</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name></person-group> (<year>2011</year>). <article-title>HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses</article-title>. <source>J. Virol.</source><volume>85</volume>, <fpage>11601</fpage>&#8211;<lpage>11614</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.05239-11</pub-id><pub-id pub-id-type="pmid">21900165</pub-id><pub-id pub-id-type="pmcid">PMC3209310</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ambati</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines</article-title>. <source>Glia</source><volume>53</volume>, <fpage>132</fpage>&#8211;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1002/glia.20262</pub-id><pub-id pub-id-type="pmid">16206161</pub-id><pub-id pub-id-type="pmcid">PMC3077280</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Happel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression</article-title>. <source>Cell. Immunol.</source><volume>252</volume>, <fpage>146</fpage>&#8211;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2007.09.008</pub-id><pub-id pub-id-type="pmid">18279847</pub-id><pub-id pub-id-type="pmcid">PMC2538679</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finley</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bardi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the &#954;-opioid receptor</article-title>. <source>J. Neuroimmunol.</source><volume>197</volume>, <fpage>114</fpage>&#8211;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.04.021</pub-id><pub-id pub-id-type="pmid">18533278</pub-id><pub-id pub-id-type="pmcid">PMC2596309</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floreani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antoniazzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mescoli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bergasa</surname><given-names>N. V.</given-names></name></person-group> (<year>2012</year>). <article-title>Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C</article-title>. <source>Eur. J. Gastroenterol. Hepatol.</source><volume>24</volume>, <fpage>427</fpage>&#8211;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1097/meg.0b013e3283509197</pub-id><pub-id pub-id-type="pmid">22293330</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>D.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>The increasing mortality burden of liver disease among opioid-dependent people: cohort study</article-title>. <source>Addiction</source><volume>106</volume>, <fpage>2186</fpage>&#8211;<lpage>2192</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.2011.03575.x</pub-id><pub-id pub-id-type="pmid">21749525</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gieraerts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Navalgund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Soetens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Jahr</surname><given-names>J.</given-names></name></person-group> (<year>1987</year>). <article-title>Increased incidence of itching and herpes simplex in patients given epidural morphine after cesarean section</article-title>. <source>Anesth. Analg.</source><volume>66</volume>, <fpage>1321</fpage>&#8211;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1213/00000539-198712000-00023</pub-id><pub-id pub-id-type="pmid">3688506</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grimm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ben-Baruch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taub</surname><given-names>D.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Resau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Opiates transdeactivate chemokine receptors: &#948; and &#956; opiate receptor&#8211;mediated heterologous desensitization</article-title>. <source>J. Exp. Med.</source><volume>188</volume>, <fpage>317</fpage>&#8211;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1084/jem.188.2.317</pub-id><pub-id pub-id-type="pmid">9670044</pub-id><pub-id pub-id-type="pmcid">PMC2212445</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiede</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Duchin</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>E. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Sharing of drug preparation equipment as a risk factor for hepatitis C</article-title>. <source>Am. J. Public Health</source><volume>91</volume>, <fpage>42</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.91.1.42</pub-id><pub-id pub-id-type="pmid">11189822</pub-id><pub-id pub-id-type="pmcid">PMC1446500</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajipirloo</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Bozorgomd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shahabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tappeh</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Karamati</surname><given-names>S. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Evaluation of alum-naltrexone adjuvant activity, on efficacy of anti-leishmania immunization with autoclaved leishmania major (MRHO/IR/75/ER) antigens in BALB/C mice</article-title>. <source>Iran. J. Parasitol.</source><volume>9</volume>, <fpage>311</fpage>. <pub-id pub-id-type="pmid">25678914</pub-id><pub-id pub-id-type="pmcid">PMC4316561</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Tyor</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Molecular targets of opiate drug abuse in neuroAIDS</article-title>. <source>Neurotox. Res.</source><volume>8</volume>, <fpage>63</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/BF03033820</pub-id><pub-id pub-id-type="pmid">16260386</pub-id><pub-id pub-id-type="pmcid">PMC4306668</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herz</surname><given-names>A.</given-names></name></person-group> (<year>1998</year>). <article-title>Multiple opiate receptors and their functional significance</article-title>. <source>J. Neural Transm. Suppl.</source><volume>18</volume>, <fpage>227</fpage>&#8211;<lpage>233</lpage>. <pub-id pub-id-type="pmid">6135743</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Rock</surname><given-names>R. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis</article-title>. <source>J. Neuroimmune Pharmacol.</source><volume>6</volume>, <fpage>528</fpage>&#8211;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9306-3</pub-id><pub-id pub-id-type="pmid">21850403</pub-id><pub-id pub-id-type="pmcid">PMC8450937</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bamdad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soleimanjahi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pakdel</surname><given-names>F. G.</given-names></name><name name-style="western"><surname>Arefian</surname><given-names>E.</given-names></name></person-group> (<year>2007a</year>). <article-title>Acute morphine administration reduces white blood cells' capability to induce innate resistance against HSV-1 infection in BALB/c mice</article-title>. <source>Neuroimmunomodulation</source><volume>14</volume>, <fpage>16</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1159/000107284</pub-id><pub-id pub-id-type="pmid">17700036</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Sabahi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Farsani</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bamdad</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine</article-title>. <source>Int. Immunol.</source><volume>21</volume>, <fpage>217</fpage>&#8211;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxn139</pub-id><pub-id pub-id-type="pmid">19174474</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Sabahi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Javan</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2007b</year>). <article-title>Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice</article-title>. <source>Microb. Pathog.</source><volume>43</volume>, <fpage>217</fpage>&#8211;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2007.06.001</pub-id><pub-id pub-id-type="pmid">17669616</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soleimanjahi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sabahi</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Withdrawal from morphine reduces cell-mediated immunity against herpes simplex virus generated by natural immunization</article-title>. <source>Neuroimmunomodulation</source><volume>19</volume>, <fpage>229</fpage>&#8211;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1159/000334768</pub-id><pub-id pub-id-type="pmid">22441539</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazani</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Karimzad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazloomi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sohrabpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>Z. M.</given-names></name><name name-style="western"><surname>Ghasemnejad</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed <italic toggle="yes">Listeria monocytogenes</italic> vaccine</article-title>. <source>Microbes Infect.</source><volume>12</volume>, <fpage>382</fpage>&#8211;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2010.02.001</pub-id><pub-id pub-id-type="pmid">20152926</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazani</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Sohrabpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazloomi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shahabi</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine</article-title>. <source>FEMS Immunol. Med. Microbiol.</source><volume>61</volume>, <fpage>54</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2010.00747.x</pub-id><pub-id pub-id-type="pmid">21054579</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminsky</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>2011</year>). <article-title>Nociceptin/orphanin FQ receptor-driven heterologous desensitization of the major HIV-1 co-receptor CXCR4</article-title>. <source>J. Neuroimmune Pharmacol.</source><volume>6</volume>, <fpage>546</fpage>&#8211;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9285-4</pub-id><pub-id pub-id-type="pmid">21656184</pub-id><pub-id pub-id-type="pmcid">PMC4011136</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapitzke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cabot</surname><given-names>P. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control</article-title>. <source>Ther. Clin. Risk Manag.</source><volume>1</volume>, <fpage>279</fpage>. <pub-id pub-id-type="pmid">18360571</pub-id><pub-id pub-id-type="pmcid">PMC1661636</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khorshidvand</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shahabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohamadzade</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daryani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tappeh</surname><given-names>K. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Mixture of alum&#8211;naloxone and alum&#8211;naltrexone as a novel adjuvant elicits immune responses for <italic toggle="yes">Toxoplasma gondii</italic> lysate antigen in BALB/c mice</article-title>. <source>Exp. Parasitol.</source><volume>162</volume>, <fpage>28</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.exppara.2016.01.001</pub-id><pub-id pub-id-type="pmid">26773164</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khachaturian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akil</surname><given-names>H.</given-names></name></person-group> (<year>1987</year>). <article-title>Opioids and pain regulation</article-title>. <source>Pain Headache.</source><volume>9</volume>, <fpage>129</fpage>&#8211;<lpage>159</lpage>. <pub-id pub-id-type="pmid">2825156</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>K.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.-J.</given-names></name><etal/></person-group>. (<year>2003a</year>). <article-title>Morphine enhances HIV infection of neonatal macrophages</article-title>. <source>Pediatr. Res.</source><volume>54</volume>, <fpage>282</fpage>&#8211;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1203/01.PDR.0000074973.83826.4C</pub-id><pub-id pub-id-type="pmid">12736382</pub-id><pub-id pub-id-type="pmcid">PMC4035124</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C. Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G. X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Morphine inhibits intrahepatic interferon-&#945; expression and enhances complete hepatitis C virus replication</article-title>. <source>J. Infect. Dis.</source><volume>196</volume>, <fpage>719</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1086/520093</pub-id><pub-id pub-id-type="pmid">17674315</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.-D.</given-names></name><name name-style="western"><surname>Pleasure</surname><given-names>D. E.</given-names></name><etal/></person-group>. (<year>2003b</year>). <article-title>Morphine enhances hepatitis C virus (HCV) replicon expression</article-title>. <source>Am. J. Pathol.</source><volume>163</volume>, <fpage>1167</fpage>&#8211;<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)63476-1</pub-id><pub-id pub-id-type="pmid">12937158</pub-id><pub-id pub-id-type="pmcid">PMC1868275</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lioy</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Olschowka</surname><given-names>J. A.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Acute morphine exposure potentiates the development of HSV-1-induced encephalitis</article-title>. <source>J. Neuroimmunol.</source><volume>172</volume>, <fpage>9</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.10.007</pub-id><pub-id pub-id-type="pmid">16325924</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokensgard</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>2002</year>). <article-title>&#954;-Opioid receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4<sup>+</sup> lymphocytes</article-title>. <source>Biochem. Pharmacol.</source><volume>63</volume>, <fpage>1037</fpage>&#8211;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(02)00875-4</pub-id><pub-id pub-id-type="pmid">11931835</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lozano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Naghavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shibuya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aboyans</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010</article-title>. <source>Lancet</source><volume>380</volume>, <fpage>2095</fpage>&#8211;<lpage>2128</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61728-0</pub-id><pub-id pub-id-type="pmid">23245604</pub-id><pub-id pub-id-type="pmcid">PMC10790329</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maartens</surname><given-names>G.</given-names></name><name name-style="western"><surname>Celum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>S. R.</given-names></name></person-group> (<year>2014</year>). <article-title>HIV infection: epidemiology, pathogenesis, treatment, and prevention</article-title>. <source>Lancet</source><volume>384</volume>, <fpage>258</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60164-1</pub-id><pub-id pub-id-type="pmid">24907868</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahajan</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Aalinkeel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S. A.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells</article-title>. <source>Curr. HIV Res.</source><volume>3</volume>, <fpage>277</fpage>&#8211;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.2174/1570162054368048</pub-id><pub-id pub-id-type="pmid">16022659</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masvekar</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>P. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Morphine enhances HIV-1 SF162-mediated neuron death and delays recovery of injured neurites</article-title>. <source>PLoS ONE</source><volume>9</volume>:<fpage>e100196</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0100196</pub-id><pub-id pub-id-type="pmid">24949623</pub-id><pub-id pub-id-type="pmcid">PMC4064991</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsunaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Isowa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kasugai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Association of polymorphism in the human &#956;-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception</article-title>. <source>Brain Behav. Immun.</source><volume>23</volume>, <fpage>931</fpage>&#8211;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2009.03.007</pub-id><pub-id pub-id-type="pmid">19341791</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Alteration of early T cell development by opioid and superantigen stimulation.</article-title><source>Adv. Exp. Med. Biol.</source><volume>493</volume>, <fpage>163</fpage>&#8211;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1007/0-306-47611-8_19</pub-id><pub-id pub-id-type="pmid">11727762</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sliker</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Eisenstein</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Opioids, opioid receptors, and the immune response</article-title>. <source>Drug Alcohol Depend.</source><volume>62</volume>, <fpage>111</fpage>&#8211;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/S0376-8716(00)00181-2</pub-id><pub-id pub-id-type="pmid">11245967</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNally</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Akil</surname><given-names>H.</given-names></name></person-group> (<year>2002</year>). <article-title>Chapter 3: Opioid peptides and their receptors: overview and function in pain modulation</article-title>, in <source>Opioid Peptides Pain Modulation.</source></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sindberg</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Disruption of gut homeostasis by opioids accelerates HIV disease progression</article-title>. <source>Front. Microbiol.</source><volume>6</volume>:<issue>643</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00643</pub-id><pub-id pub-id-type="pmid">26167159</pub-id><pub-id pub-id-type="pmcid">PMC4481162</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mojadadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khansarinejad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soleimanjahi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bamdad</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice</article-title>. <source>Cell. Mol. Immunol.</source><volume>6</volume>, <fpage>111</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2009.15</pub-id><pub-id pub-id-type="pmid">19403060</pub-id><pub-id pub-id-type="pmcid">PMC4002647</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>LeSage</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>HIV-1 gp120 primes lymphocytes for opioid-induced, &#946;-arrestin 2-dependent apoptosis</article-title>. <source>Biochim. Biophys. Acta</source><volume>1793</volume>, <fpage>1366</fpage>&#8211;<lpage>1371</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2009.05.007</pub-id><pub-id pub-id-type="pmid">19477204</pub-id><pub-id pub-id-type="pmcid">PMC2716560</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Dweik</surname><given-names>D.</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roll</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings</article-title>. <source>Am. J. Drug Alcohol Abuse</source><volume>41</volume>, <fpage>88</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.3109/00952990.2014.983274</pub-id><pub-id pub-id-type="pmid">25490610</pub-id><pub-id pub-id-type="pmcid">PMC4638227</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meucci</surname><given-names>O.</given-names></name></person-group> (<year>2014</year>). <article-title>Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by &#956;-opioid receptors</article-title>. <source>Int. Rev. Neurobiol.</source><volume>118</volume>, <fpage>105</fpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801284-0.00005-1</pub-id><pub-id pub-id-type="pmid">25175863</pub-id><pub-id pub-id-type="pmcid">PMC4369781</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Mathers</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Des Jarlais</surname><given-names>D.</given-names></name><name name-style="western"><surname>Horyniak</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews</article-title>. <source>Lancet</source><volume>378</volume>, <fpage>571</fpage>&#8211;<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61097-0</pub-id><pub-id pub-id-type="pmid">21802134</pub-id><pub-id pub-id-type="pmcid">PMC3285467</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ninkovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of the mu-opioid receptor in opioid modulation of immune function</article-title>. <source>Amino Acids</source><volume>45</volume>, <fpage>9</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00726-011-1163-0</pub-id><pub-id pub-id-type="pmid">22170499</pub-id><pub-id pub-id-type="pmcid">PMC3912755</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odunayo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dodam</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Kerl</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>DeClue</surname><given-names>A. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Immunomodulatory effects of opioids</article-title>. <source>J. Vet. Emerg. Crit. Care</source><volume>20</volume>, <fpage>376</fpage>&#8211;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-4431.2010.00561.x</pub-id><pub-id pub-id-type="pmid">20731802</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payabvash</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beheshtian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salmasi</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Kiumehr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghahremani</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Tavangar</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver</article-title>. <source>Life Sci.</source><volume>79</volume>, <fpage>972</fpage>&#8211;<lpage>980</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2006.05.008</pub-id><pub-id pub-id-type="pmid">16750225</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pello</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mu&#241;oz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parrillas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Frade</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Toro</surname><given-names>M. J.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Ligand stabilization of CXCR4/&#948;-opioid receptor heterodimers reveals a mechanism for immune response regulation</article-title>. <source>Eur. J. Immunol.</source><volume>38</volume>, <fpage>537</fpage>&#8211;<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200737630</pub-id><pub-id pub-id-type="pmid">18200497</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lokensgard</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Bidlack</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>&#954;-opioid receptor agonist suppression of HIV-1 expression in CD4<sup>+</sup> lymphocytes</article-title>. <source>Biochem. Pharmacol.</source><volume>61</volume>, <fpage>1145</fpage>&#8211;<lpage>1151</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00574-3</pub-id><pub-id pub-id-type="pmid">11301048</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Portoghese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sannerud</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balfour</surname><given-names>H. H.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1990</year>). <article-title>Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures</article-title>. <source>AIDS</source><volume>4</volume>, <fpage>869</fpage>&#8211;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1097/00002030-199009000-00006</pub-id><pub-id pub-id-type="pmid">2174676</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilakka-Kanthikeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>M. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Interaction of drugs of abuse and microRNA with HIV: a brief review</article-title>. <source>Front. Microbiol.</source><volume>6</volume>:<issue>967</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00967</pub-id><pub-id pub-id-type="pmid">26483757</pub-id><pub-id pub-id-type="pmcid">PMC4586453</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prottengeier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koutsilieri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scheller</surname><given-names>C.</given-names></name></person-group> (<year>2014</year>). <article-title>The effects of opioids on HIV reactivation in latently-infected T-lymphoblasts</article-title>. <source>AIDS Res. Ther.</source><volume>11</volume>, <fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/1742-6405-11-17</pub-id><pub-id pub-id-type="pmid">25013451</pub-id><pub-id pub-id-type="pmcid">PMC4091651</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proudnikov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Randesi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment</article-title>. <source>J. Infect. Dis.</source><volume>205</volume>, <fpage>1745</fpage>&#8211;<lpage>1756</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis264</pub-id><pub-id pub-id-type="pmid">22457278</pub-id><pub-id pub-id-type="pmcid">PMC3415853</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proudnikov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Randesi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yuferov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history</article-title>. <source>J. Acquir. Immune. Defic. Syndr.</source><volume>63</volume>, <fpage>17</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e318285cd0c</pub-id><pub-id pub-id-type="pmid">23392455</pub-id><pub-id pub-id-type="pmcid">PMC3625517</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purohit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rapaka</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shurtleff</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Do opioids activate latent HIV-1 by down-regulating anti-HIV microRNAs?</article-title><source>J. Neuroimmune Pharmacol.</source><volume>7</volume>, <fpage>519</fpage>&#8211;<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9356-1</pub-id><pub-id pub-id-type="pmid">22527633</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Risdahl</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Molitor</surname><given-names>T. W.</given-names></name></person-group> (<year>1998</year>). <article-title>Opiates and infection</article-title>. <source>J. Neuroimmunol.</source><volume>83</volume>, <fpage>4</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-5728(97)00216-6</pub-id><pub-id pub-id-type="pmid">9610668</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>2003</year>). <article-title>Opioid G protein-coupled receptors: signals at the crossroads of inflammation</article-title>. <source>Trends Immunol.</source><volume>24</volume>, <fpage>116</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/S1471-4906(03)00003-6</pub-id><pub-id pub-id-type="pmid">12615205</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>A.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Oppenheim</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Bidirectional heterologous desensitization of opioid and chemokine receptors</article-title>. <source>Ann. N.Y. Acad. Sci.</source><volume>917</volume>, <fpage>19</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05369.x</pub-id><pub-id pub-id-type="pmid">11268344</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojavin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bussiere</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Eisenstein</surname><given-names>T. K.</given-names></name></person-group> (<year>1993</year>). <article-title>Morphine treatment <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic> decreases phagocytic functions of murine macrophages</article-title>. <source>Life Sci.</source><volume>53</volume>, <fpage>997</fpage>&#8211;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(93)90122-J</pub-id><pub-id pub-id-type="pmid">8361330</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouveix</surname><given-names>B.</given-names></name></person-group> (<year>1992</year>). <article-title>Opiates and immune function. consequences on infectious diseases with special reference to AIDS</article-title>. <source>Therapie</source><volume>47</volume>, <fpage>503</fpage>&#8211;<lpage>512</lpage>. <pub-id pub-id-type="pmid">1301643</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ninkovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charboneau</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections</article-title>. <source>J. Neuroimmune Pharmacol.</source><volume>6</volume>, <fpage>442</fpage>&#8211;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-011-9292-5</pub-id><pub-id pub-id-type="pmid">21789507</pub-id><pub-id pub-id-type="pmcid">PMC3601186</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacerdote</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>Opioids and the immune system</article-title>. <source>Palliat. Med.</source><volume>20</volume>, <fpage>9</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="pmid">16764216</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacerdote</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gaspani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Panerai</surname><given-names>A. E.</given-names></name></person-group> (<year>2000</year>). <article-title>The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice</article-title>. <source>Ann. N.Y. Acad. Sci.</source><volume>917</volume>, <fpage>755</fpage>&#8211;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05440.x</pub-id><pub-id pub-id-type="pmid">11268404</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacerdote</surname><given-names>P.</given-names></name><name name-style="western"><surname>di San Secondo</surname><given-names>V. E.</given-names></name><name name-style="western"><surname>Sirchia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Panerai</surname><given-names>A. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines</article-title>. <source>Clin. Exp. Immunol.</source><volume>113</volume>, <fpage>465</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00680.x</pub-id><pub-id pub-id-type="pmid">9737678</pub-id><pub-id pub-id-type="pmcid">PMC1905056</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pilakka-Kanthikeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Jayant</surname><given-names>R. D.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Therapeutical neurotargeting via magnetic nanocarrier: implications to opiate-induced neuropathogenesis and neuroaids</article-title>. <source>J. Biomed. Nanotechnol.</source><volume>11</volume>, <fpage>1722</fpage>&#8211;<lpage>1733</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2015.2108</pub-id><pub-id pub-id-type="pmid">26502636</pub-id><pub-id pub-id-type="pmcid">PMC4624254</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hennus</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Mokhtari-Azad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shokri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hodemaekers</surname><given-names>H. M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Opioid receptors control viral replication in the airways</article-title>. <source>Crit. Care Med.</source><volume>41</volume>, <fpage>205</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0b013e31826767a8</pub-id><pub-id pub-id-type="pmid">23222260</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tavakoli-Yaraki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yavarian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bont</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mokhtari-Azad</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Prevalence of human respiratory syncytial virus circulating in Iran</article-title>. <source>J. Infect. Public Health.</source><volume>9</volume>, <fpage>125</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2015.05.005</pub-id><pub-id pub-id-type="pmid">26143136</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samikkannu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ranjith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Pimentel</surname><given-names>E.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>HIV-1 gp120 and morphine induced oxidative stress: role in cell cycle regulation</article-title>. <source>Front. Microbiol.</source><volume>6</volume>:<issue>614</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00614</pub-id><pub-id pub-id-type="pmid">26157430</pub-id><pub-id pub-id-type="pmcid">PMC4477635</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takasaki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiraki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuraishi</surname><given-names>Y.</given-names></name></person-group> (<year>2007</year>). <article-title>Effects of loperamide on mechanical allodynia induced by herpes simplex virus type-1 in mice</article-title>. <source>J. Pharmacol. Sci.</source><volume>104</volume>, <fpage>218</fpage>&#8211;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.FP0070294</pub-id><pub-id pub-id-type="pmid">17598951</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takasaki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiraki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuraishi</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>Morphine inhibits herpetic allodynia through &#956;-opioid receptors induced in A&#946;-fiber neurons</article-title>. <source>Neuroreport</source><volume>19</volume>, <fpage>975</fpage>&#8211;<lpage>979</lpage>. <pub-id pub-id-type="doi">10.1097/WNR.0b013e328302f123</pub-id><pub-id pub-id-type="pmid">18521004</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mazloomi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tappeh</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Seyedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohammadzadeh</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against <italic toggle="yes">Plasmodium berghei</italic></article-title>. <source>Immunol. Invest.</source><volume>43</volume>, <fpage>653</fpage>&#8211;<lpage>666</lpage>. <pub-id pub-id-type="doi">10.3109/08820139.2014.914531</pub-id><pub-id pub-id-type="pmid">25020077</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Gekker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P. K.</given-names></name></person-group> (<year>1998</year>). <article-title>&#948;-Opioid suppression of human immunodeficiency virus-1 expression in T cells (Jurkat)</article-title>. <source>Biochem. Pharmacol.</source><volume>56</volume>, <fpage>289</fpage>&#8211;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(98)00155-5</pub-id><pub-id pub-id-type="pmid">9744564</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shavit</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Terman</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Liebeskind</surname><given-names>J. C.</given-names></name></person-group> (<year>1984</year>). <article-title>Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity</article-title>. <source>Science</source><volume>223</volume>, <fpage>188</fpage>&#8211;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1126/science.6691146</pub-id><pub-id pub-id-type="pmid">6691146</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheridan</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>J. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Modulation of the innate immune response to HSV-1 following acute administration of morphine: role of hypothalamo-pituitary-adrenal axis</article-title>. <source>J. Neuroimmunol.</source><volume>158</volume>, <fpage>145</fpage>&#8211;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.09.001</pub-id><pub-id pub-id-type="pmid">15589048</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Short</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Kroeze</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Pathogenesis of influenza-induced acute respiratory distress syndrome</article-title>. <source>Lancet Infect. Dis.</source><volume>14</volume>, <fpage>57</fpage>&#8211;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70286-X</pub-id><pub-id pub-id-type="pmid">24239327</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpkins</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Alailima</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.</given-names></name></person-group> (<year>1986</year>). <article-title>The effect of enkephalins and prostaglandins on O 2&#8722; release by neutrophils</article-title>. <source>J. Surg. Res.</source><volume>41</volume>, <fpage>645</fpage>&#8211;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1016/0022-4804(86)90090-9</pub-id><pub-id pub-id-type="pmid">3023754</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singhal</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kapasi</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Franki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>N.</given-names></name></person-group> (<year>1998</year>). <article-title>Morphine enhances macrophage apoptosis</article-title>. <source>J. Immunol.</source><volume>160</volume>, <fpage>1886</fpage>&#8211;<lpage>1893</lpage>. <pub-id pub-id-type="pmid">9469450</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solbrig</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Adrian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Perng</surname><given-names>G.-C.</given-names></name></person-group> (<year>2006</year>). <article-title>Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model</article-title>. <source>Neurobiol. Dis.</source><volume>23</volume>, <fpage>612</fpage>&#8211;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2006.05.014</pub-id><pub-id pub-id-type="pmid">16843674</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steele</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>2003</year>). <article-title>&#956;-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication</article-title>. <source>Virology</source><volume>309</volume>, <fpage>99</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/S0042-6822(03)00015-1</pub-id><pub-id pub-id-type="pmid">12726730</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steele</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bednar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Interactions between opioid and chemokine receptors: heterologous desensitization</article-title>. <source>Cytokine Growth Factor Rev.</source><volume>13</volume>, <fpage>209</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/S1359-6101(02)00007-2</pub-id><pub-id pub-id-type="pmid">12486875</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Opioid receptors</article-title>. <source>Annu. Rev. Med.</source><volume>67</volume>, <fpage>433</fpage>&#8211;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-med-062613-093100</pub-id><pub-id pub-id-type="pmid">26332001</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>C. W.</given-names></name></person-group> (<year>2009</year>). <article-title>The evolution of vertebrate opioid receptors</article-title>. <source>Front. Biosci.</source><volume>14</volume>:<fpage>1247</fpage>&#8211;<lpage>1269</lpage>. <pub-id pub-id-type="doi">10.2741/3306</pub-id><pub-id pub-id-type="pmid">19273128</pub-id><pub-id pub-id-type="pmcid">PMC3070387</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoppelenburg</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hennus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plantinga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huis in 't Veld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walk</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Local IL-17A potentiates early neutrophil recruitment to the respiratory tract during severe RSV infection</article-title>. <source>PLoS ONE</source><volume>8</volume>:<fpage>e78461</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0078461</pub-id><pub-id pub-id-type="pmid">24194936</pub-id><pub-id pub-id-type="pmcid">PMC3806820</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strazza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alexaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Passic</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Meucci</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pirrone</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Effect of mu-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells</article-title>. <source>BMC Res. Notes</source><volume>7</volume>:<fpage>752</fpage>. <pub-id pub-id-type="doi">10.1186/1756-0500-7-752</pub-id><pub-id pub-id-type="pmid">25338959</pub-id><pub-id pub-id-type="pmcid">PMC4216373</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundar</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Kamaraju</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bitonte</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Gollapudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>W. H.</given-names></name><etal/></person-group>. (<year>1996</year>). <article-title>Endogenous opioids and HIV infection</article-title>. <source>Adv. Exp. Med. Biol.</source><volume>402</volume>, <fpage>53</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4613-0407-4_8</pub-id><pub-id pub-id-type="pmid">8787643</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization</article-title>. <source>J. Leukoc. Biol.</source><volume>74</volume>, <fpage>1074</fpage>&#8211;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0203067</pub-id><pub-id pub-id-type="pmid">12972507</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahamtan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tavakoli-Yaraki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rygiel</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Mokhtari-Azad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Effects of cannabinoids and their receptors on viral infections</article-title>. <source>J. Med. Virol.</source><volume>88</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24292</pub-id><pub-id pub-id-type="pmid">26059175</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taub</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Eisenstein</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T. J.</given-names></name></person-group> (<year>1991</year>). <article-title>Immunomodulatory activity of mu-and kappa-selective opioid agonists</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>88</volume>, <fpage>360</fpage>&#8211;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.88.2.360</pub-id><pub-id pub-id-type="pmid">1846441</pub-id><pub-id pub-id-type="pmcid">PMC50810</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tennant</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>D.</given-names></name></person-group> (<year>1995</year>). <article-title>Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts</article-title>. <source>J. Addict. Dis.</source><volume>14</volume>, <fpage>35</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1300/J069v14n03_03</pub-id><pub-id pub-id-type="pmid">8555278</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Padgett</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Dhabhar</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>J. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids</article-title>. <source>Brain Behav. Immun.</source><volume>19</volume>, <fpage>153</fpage>&#8211;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2004.07.001</pub-id><pub-id pub-id-type="pmid">15664788</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsui</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Page</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs</article-title>. <source>JAMA Intern. Med.</source><volume>174</volume>, <fpage>1974</fpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2014.5416</pub-id><pub-id pub-id-type="pmid">25347412</pub-id><pub-id pub-id-type="pmcid">PMC4506774</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turchan-Cholewo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dimayuga</surname><given-names>F. O.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation</article-title>. <source>J. Neurochem.</source><volume>108</volume>, <fpage>202</fpage>&#8211;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05756.x</pub-id><pub-id pub-id-type="pmid">19054280</pub-id><pub-id pub-id-type="pmcid">PMC2749479</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turchan-Cholewo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dimayuga</surname><given-names>F. O.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>P. E.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia</article-title>. <source>J. Neurosci. Res.</source><volume>86</volume>, <fpage>2100</fpage>&#8211;<lpage>2110</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21653</pub-id><pub-id pub-id-type="pmid">18338799</pub-id><pub-id pub-id-type="pmcid">PMC2760290</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>UNODC</collab></person-group> (<year>2015</year>). <source>World Drug Report (United Nations publication, Sales No. E.12.XI.1</source>).</mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Booze</surname><given-names>R. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Delta opioid agonists attenuate TAT(1-72)-induced oxidative stress in SK-N-SH cells</article-title>. <source>Neurotoxicology</source><volume>27</volume>, <fpage>101</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2005.07.008</pub-id><pub-id pub-id-type="pmid">16168488</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.-Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Morphine withdrawal enhances hepatitis C virus replicon expression</article-title>. <source>Am. J. Pathol.</source><volume>167</volume>, <fpage>1333</fpage>&#8211;<lpage>1340</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)61220-5</pub-id><pub-id pub-id-type="pmid">16251417</pub-id><pub-id pub-id-type="pmcid">PMC1603791</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barke</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Charboneau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Opiate abuse, innate immunity, and bacterial infectious diseases</article-title>. <source>Arch. Immunol. Ther. Exp.</source><volume>56</volume>, <fpage>299</fpage>&#8211;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1007/s00005-008-0035-0</pub-id><pub-id pub-id-type="pmid">18836861</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W. Z.</given-names></name></person-group> (<year>2011</year>). <article-title>Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission</article-title>. <source>Life Sci.</source><volume>88</volume>, <fpage>972</fpage>&#8211;<lpage>979</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2010.10.029</pub-id><pub-id pub-id-type="pmid">21056582</pub-id><pub-id pub-id-type="pmcid">PMC3100448</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W.-Z.</given-names></name></person-group> (<year>2005</year>). <article-title>Morphine inhibits CD8<sup>+</sup> T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells</article-title>. <source>J. Leukoc. Biol.</source><volume>78</volume>, <fpage>772</fpage>&#8211;<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0305167</pub-id><pub-id pub-id-type="pmid">16000393</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M. Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W. Z.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes</article-title>. <source>Am. J. Pathol.</source><volume>178</volume>, <fpage>41</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2010.11.042</pub-id><pub-id pub-id-type="pmid">21224041</pub-id><pub-id pub-id-type="pmcid">PMC3069926</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dusheiko</surname><given-names>G. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Hepatitis, C</article-title>. <source>Lancet</source><volume>385</volume>, <fpage>1124</fpage>&#8211;<lpage>1135</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)62401-6</pub-id><pub-id pub-id-type="pmid">25687730</pub-id><pub-id pub-id-type="pmcid">PMC4878852</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weeks</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Alston</surname><given-names>N. I.</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rialas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>G. B.</given-names></name></person-group> (<year>2001</year>). <article-title>Morphine reduces herpes simplex virus-1 pathogenesis in the murine flank</article-title>. <source>Int. J. Mol. Med.</source><volume>8</volume>, <fpage>303</fpage>&#8211;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.8.3.303</pub-id><pub-id pub-id-type="pmid">11494059</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitley</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Roizman</surname><given-names>B.</given-names></name></person-group> (<year>2001</year>). <article-title>Herpes simplex virus infections</article-title>. <source>Lancet</source><volume>357</volume>, <fpage>1513</fpage>&#8211;<lpage>1518</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(00)04638-9</pub-id><pub-id pub-id-type="pmid">11377626</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wittert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pyle</surname><given-names>D.</given-names></name></person-group> (<year>1996</year>). <article-title>Tissue distribution of opioid receptor gene expression in the rat</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>218</volume>, <fpage>877</fpage>&#8211;<lpage>881</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1996.0156</pub-id><pub-id pub-id-type="pmid">8579608</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W.</given-names></name></person-group> (<year>2010</year>). <article-title>Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users</article-title>. <source>PLoS ONE</source><volume>5</volume>:<fpage>e9602</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0009602</pub-id><pub-id pub-id-type="pmid">20231901</pub-id><pub-id pub-id-type="pmcid">PMC2834757</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arnatt</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dever</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Selley</surname><given-names>D. E.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities</article-title>. <source>Medchemcomm</source><volume>4</volume>, <fpage>847</fpage>&#8211;<lpage>851</lpage>. <pub-id pub-id-type="doi">10.1039/c3md00080j</pub-id><pub-id pub-id-type="pmid">23682308</pub-id><pub-id pub-id-type="pmcid">PMC3652433</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W. Z.</given-names></name></person-group> (<year>2006</year>). <article-title>Drug abuse, innate immunity and hepatitis C virus</article-title>. <source>Rev. Med. Virol.</source><volume>16</volume>, <fpage>311</fpage>&#8211;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.508</pub-id><pub-id pub-id-type="pmid">16933366</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>C. P.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Alcohol potentiates hepatitis C virus replicon expression</article-title>. <source>Hepatology</source><volume>38</volume>, <fpage>57</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1053/jhep.2003.50295</pub-id><pub-id pub-id-type="pmid">12829987</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitting</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>K. F.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at &#956;-opioid receptor-expressing glia</article-title>. <source>Brain</source><volume>134</volume>, <fpage>3616</fpage>&#8211;<lpage>3631</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awr281</pub-id><pub-id pub-id-type="pmid">22102648</pub-id><pub-id pub-id-type="pmcid">PMC3235561</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>MORs</term><def><p>&#956;-opioid receptors</p></def></def-item><def-item><term>DORs</term><def><p>&#948;-opioid receptors</p></def></def-item><def-item><term>KORs</term><def><p>&#954;-opioid receptors</p></def></def-item><def-item><term>GPCRs</term><def><p>G-protein-coupled receptors</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen-activated protein kinases</p></def></def-item><def-item><term>IP3, inositol-1, 4</term><def><p>5-triphosphate</p></def></def-item><def-item><term>CCR</term><def><p>C-C chemokine receptor</p></def></def-item><def-item><term>CXCR</term><def><p>C-X-C chemokine receptor</p></def></def-item><def-item><term>CXCL</term><def><p>C-X-C motif ligand</p></def></def-item><def-item><term>CCL</term><def><p>C-C motif ligand</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>Th</term><def><p>T-helper</p></def></def-item><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>miRNAs</term><def><p>microRNA</p></def></def-item><def-item><term>3&#8242;-UTR</term><def><p>3&#8242;-untranslatet region</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term>NF-&#954;B</term><def><p>nuclear factor-kappa B</p></def></def-item><def-item><term>gp</term><def><p>glycoprotein</p></def></def-item><def-item><term>Tat</term><def><p>transactivator of transcription</p></def></def-item><def-item><term>TNF-&#945;</term><def><p>tumor necrosis factor-&#945;</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>HCV</term><def><p>hepatitis C virus</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>IRF</term><def><p>interferon regulatory factor</p></def></def-item><def-item><term>SOCS-3</term><def><p>suppressor of cytokine signaling 3</p></def></def-item><def-item><term>PIAS-3</term><def><p>protein inhibitor of activated STAT3</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>BALF</term><def><p>bronchoalveolar lavage fluid</p></def></def-item><def-item><term>RSV</term><def><p>respiratory syncytial virus</p></def></def-item><def-item><term>HSV</term><def><p>herpes simplex virus</p></def></def-item><def-item><term>BBB</term><def><p>blood-brain barrier.</p></def></def-item></def-list></glossary></back></article></pmc-articleset>